Kidney Week 2017
Phosphate binder use is associated with a 25% and 37% decreased risk of death from infection-related causes and all-causes, respectively, compared with non-users.
Achieving a phosphate value of 1.4 mmol/L seemed optimal.
Intravenous iron and erythropoietin produced a similar hemoglobin response among hemodialysis patients with moderate anemia.
From 2004 to 2012, the incidence of AKI increased from 4.9% to 14.2% among CABG patients and from 2.7% to 8.8% among PCI patients.
HD patients with untreated or ineffectively treated anemia prior to dialysis initiation were more likely to die than those who had consistently well-treated anemia.
In a phase 3 trial, acute kidney injury developed in 13.2% of patients undergoing invasive coronary angiography compared with 5.6% of those undergoing computed tomography angiography.
Patients with autosomal dominant polycystic kidney disease treated with tolvaptan experienced a 35% decrease in the annual rate of decline in eGFR.
Among kidney transplant recipients who died with a functioning graft, the cause of death was reported as unknown for 64% of them.
The 5-year survival rates was 80.7% for patients in the lowest quartile of serum uric acid at HD initiation versus 89.6% for those in the highest quartile.
Likelihood of stone formation increases with higher calcium oxalate and calcium phosphate relative supersaturation.
Study reveals 2-fold higher incidence of bacteremia among dialysis patients with low and high serum sodium levels.
In a pilot study, investigators observed no harmful effects from etelcalcetide injection, and 5 of 10 of patients had a greater than 50% decline in PTH levels.
Each 0.1 increase in WHR is associated with a 1.7-fold increased risk of cardiovascular death.
Patients with non-dialysis chronic kidney disease and iron deficiency anemia treated with ferric citrate experienced significant declines in FGF23 regardless of change in serum phosphorus.
Study documents occurrence of rapid correction in 44.3% of hospitalized patients.
Therapy with paricalcitol alone achieved the greatest decline in intact parathyroid hormone among hemodialysis with secondary hyperparathyroidism.
Patients with post-traumatic stress disorder had an 11% lower death risk 1 year after initiating dialysis than those without the disorder, study finds.
Even at very low levels, residual kidney function in hemodialysis patients clears uremic solutes.
Each 1 standard deviation in baseline uric acid levels was associated with a significant 80% increased odds of rapid kidney function decline.
Patients in the lowest quartiles of urinary uromodulin had increased risks of end-stage renal disease and rapid kidney function decline.
In a study, end-stage renal disease was 31% more likely to develop in CKD patients with versus without anemia.
From 1995 to 2015, the prevalence of hypertension and diabetes among patients starting hemodialysis increased from 67.9% to 87.6% and from 43.1% to 59.6%, respectively.
In a study, end-stage renal disease developed in 56% of patients discharged from a hospital with acute kidney injury requiring dialysis.
High levels of parathyroid hormone and fibroblast growth factor 23 in CKD patients are associated with need for renal replacement therapy or a 50% or greater decline in eGFR.
After adjusting for confounders, patients on intensive home hemodialysis and recipients of deceased-donor kidneys showed no significant difference in death risk
CKD patients in the 3rd and 4th quartiles of c-terminal serum fibroblast growth factor 23 had a 74% and 73% higher risk for anemia compared with those in the 1st quartile.
Timing of AKI after urgent percutaneous coronary intervention affects risk of significant kidney function loss 1 year after the procedure.
US veterans who underwent coronary artery bypass grafting versus percutaneous coronary intervention prior to starting dialysis had a 28% lower risk of death.
Proteinuria and renin-angiotensin-aldosterone system inhibitors are independently associated with a significant 6-fold increased odds for anemia in patients with diabetic nephropathy.
Intact parathyroid hormone levels decline in proportion with SHPT severity in patients taking the drug.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)